Abstract | OBJECTIVES: MATERIALS AND METHODS: The benefit of prolonged infusion was analyzed by comparing the results from a Phase II study using 6 h infusion of BPA-f with those obtained from a Phase I/II study using 2 h of infusion. Median survival time (MST) from diagnosis, patient baseline characteristics, salvage treatment and severe adverse events were considered in the comparison. RESULTS: MST increased significantly, from 12.8 (95% confidence interval or CI: 10.3-14.0) months with 2 h infusion to 17.7 (95% CI: 13.6-19.9) months with 6 h of infusion. The fraction of patients with WHO grade 3-4 adverse events was similar in the two studies at 13% and 14%, respectively. CONCLUSION: Prolonged infusion was found to be beneficial for the efficacy of BNCT and it is suggested that 6 h infusion of BPA-f should be used in future trials of BNCT for GBM. BNCT, which is a single-day treatment with mild side effects, should be assessed in a controlled trial, as an alternative to 30 daily fractions of conventional fractionated photon therapy over a period of 6 weeks.
|
Authors | K Sköld, B H-Stenstam, A Z Diaz, V Giusti, L Pellettieri, J W Hopewell |
Journal | Acta neurologica Scandinavica
(Acta Neurol Scand)
Vol. 122
Issue 1
Pg. 58-62
(Jul 2010)
ISSN: 1600-0404 [Electronic] Denmark |
PMID | 19951268
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 4-boronophenylalanine-fructose
- Boron Compounds
- Fructose
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Boron Compounds
(administration & dosage)
- Boron Neutron Capture Therapy
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Fructose
(administration & dosage, analogs & derivatives)
- Glioblastoma
(mortality, radiotherapy)
- Humans
- Infusions, Intravenous
- Kaplan-Meier Estimate
- Middle Aged
- Salvage Therapy
- Young Adult
|